(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-0.10%) $82.55
(0.69%) $2.04
(-0.58%) $2 344.10
(-1.16%) $27.34
(-0.17%) $959.90
(0.08%) $0.933
(0.09%) $10.99
(0.03%) $0.796
(0.01%) $93.31
Live Chart Being Loaded With Signals
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies...
Stats | |
---|---|
今日成交量 | 1.01M |
平均成交量 | 167 616 |
市值 | 108.71M |
EPS | $0 ( 2024-03-28 ) |
Last Dividend | $0.130 ( 2015-11-06 ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.25 |
ATR14 | $0.0570 (1.89%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Leonard Braden Michael | Buy | 170 589 | Common Stock, par value $0.001 per share |
2024-03-18 | Leonard Braden Michael | Buy | 113 777 | Common Stock, par value $0.001 per share |
2024-03-15 | Leonard Braden Michael | Buy | 0 | Common Stock, par value $0.001 per share |
2024-03-15 | Leonard Braden Michael | Sell | 0 | Common Stock, par value $0.001 per share |
2024-03-04 | Gaiero David G | Buy | 2 373 | Common Stock |
INSIDER POWER |
---|
11.44 |
Last 95 transactions |
Buy: 1 923 587 | Sell: 1 715 632 |
音量 相关性
Cyteir Therapeutics, Inc. 相关性
10 最正相关 | |
---|---|
EBACU | 0.891 |
TCMD | 0.875 |
ECHO | 0.873 |
TZPSU | 0.872 |
WULF | 0.871 |
TZPS | 0.869 |
JNCE | 0.869 |
MBTCU | 0.868 |
RBNC | 0.866 |
NLTX | 0.865 |
10 最负相关 | |
---|---|
VIASP | -0.896 |
STBA | -0.894 |
CMBM | -0.893 |
FBNC | -0.893 |
MMAC | -0.893 |
TRST | -0.892 |
LSAQ | -0.891 |
CVCY | -0.891 |
OPI | -0.891 |
VGFC | -0.891 |
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Cyteir Therapeutics, Inc. 相关性 - 货币/商品
Cyteir Therapeutics, Inc. 财务报表
Annual | 2022 |
营收: | $0 |
毛利润: | $-1.38M (0.00 %) |
EPS: | $-1.250 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.38M (0.00 %) |
EPS: | $-1.250 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.201 |
FY | 2020 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.070 |
Financial Reports:
No articles found.
Cyteir Therapeutics, Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0100 | 2009-08-06 |
Last Dividend | $0.130 | 2015-11-06 |
Next Dividend | $0 | N/A |
Payout Date | 2015-11-25 | |
Next Payout Date | N/A | |
# dividends | 26 | -- |
Total Paid Out | $2.66 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.76 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.236 | 1.200 | -7.86 | -9.43 | [0 - 0.3] |
returnOnEquityTTM | -0.231 | 1.500 | -3.68 | -5.52 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 21.89 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 21.66 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 21.65 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.000122 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 39.40 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.716 | 2.00 | -0.239 | -0.477 | [0 - 30] |
freeCashFlowPerShareTTM | -0.724 | 2.00 | -0.362 | -0.724 | [0 - 20] |
debtEquityRatioTTM | 0.000128 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1 611.81 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 2.08 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.52 | 1.000 | -0.457 | 0 | [1 - 100] |
returnOnEquityTTM | -0.231 | 2.50 | -2.37 | -5.52 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.724 | 2.00 | -0.241 | -0.724 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.716 | 2.00 | -0.239 | -0.477 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -0.983 |
Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。